免疫检查点抑制剂治疗相关的炎症性皮疹:单中心回顾性分析,按毒性分层及对管理的影响
研究回顾性分析了2016—2018年耶鲁-纽黑文医院肿瘤皮肤科门诊及住院会诊中,因免疫检查点抑制剂治疗出现皮疹的98例患者(51男47女),共发生103次炎症性皮疹。仅24.3%(25/103)需中断免疫治疗,多见于免疫性大疱性(7/8;87.5%)、苔藓样(8/26;30.8%)、斑丘疹样(6/18;33.3%)及Stevens-Johnson综合征样(2/2;100%)反应。再次挑战后仅3/16(18.8%)出现2级或3级 flare。90.3%(93/103)的皮疹经皮肤科治疗或中断免疫治疗后缓解。
要点
- 大多数皮疹(90.3%)经皮肤科治疗或中断免疫治疗可缓解。
- 免疫性大疱性(87.5%)和剥脱性皮疹常需中断免疫治疗。
- 再次挑战后2级或3级 flare发生率为18.8%(3/16)。
核心结论
- 免疫检查点抑制剂治疗可出现多种炎症性皮疹,严重程度不一。
- 多数皮疹对局部治疗有反应,但免疫性大疱性和剥脱性皮疹常导致免疫治疗中断。
- 提高认识和早期识别可减少不必要的免疫治疗中断。
研究设计与样本
- 单中心回顾性研究,纳入2016—2018年耶鲁-纽黑文医院肿瘤皮肤科门诊或住院皮肤科会诊中,因免疫治疗期间出现皮疹而转诊的患者。
- 共98例患者(51男,47女)接受检查点抑制剂治疗,发生103次炎症性皮疹。
主要发现
- 103次皮疹的平均潜伏期为0.2—17.7个月。
- 25/103(24.3%)需中断免疫治疗,其中免疫性大疱性7/8(87.5%)、苔藓样8/26(30.8%)、斑丘疹样6/18(33.3%)、Stevens-Johnson综合征样2/2(100%)。
- 16例中断免疫治疗的患者中,再次挑战后3例(18.8%)出现2级或3级 flare。
- 93/103(90.3%)的皮疹经皮肤科治疗或中断免疫治疗后缓解。
临床怎么用
- 原文结论指出,提高认识和早期识别可减少不必要的免疫治疗中断;多数皮疹经皮肤科治疗或中断免疫治疗可缓解。
局限性
- 本研究为单中心三级医疗中心的回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is increasing recognition of distinct inflammatory eruptions associated with checkpoint inhibitors. A better understanding of their severity, therapeutic response, and impact on cancer treatment is needed. OBJECTIVE: To analyze the different rashes associated with immunotherapy referred to our institution's oncodermatology clinic and inpatient consultative service and to evaluate their therapeutic response and impact on immunotherapy. METHODS: We retrospectively reviewed the medical records of patients referred to the oncodermatology clinic or inpatient dermatology service during 2016-2018 at Yale-New Haven Hospital for eruptions that developed during immunotherapy. RESULTS: In total, 98 patients (51 men, 47 women) treated with checkpoint inhibitors developed 103 inflammatory eruptions, with a range of mean latency of 0.2-17.7 months. A minority of patients (25/103; 24.3%) required immunotherapy interruption; most of these cases involved immunobullous (7/8; 87.5%), lichenoid (8/26; 30.8%), maculopapular (6/18; 33.3%), and Stevens-Johnson syndrome-like (2/2, 100%) reactions. Only 3 of 16 (18.8%) patients who had their immunotherapy interrupted had a grade 2 or 3 flare on rechallenge. Most reactions (93/103; 90.3%) responded to dermatologic therapy or immunotherapy interruption. LIMITATIONS: This was a retrospective study from a single tertiary care center. CONCLUSION: A variety of inflammatory reactions might occur from immunotherapy with differing degrees of severity. While most rashes responded to topical treatment, immunobullous and exfoliative presentations frequently interrupted immunotherapy. Increased awareness and early recognition could reduce the need for unnecessary immunotherapy interruption.
引用
- Coleman E, Ko C, Dai F, et al. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2018. PMID: 30399387. doi:10.1016/j.jaad.2018.10.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。